Chugai Pharmaceutical Co (4519) Price & Analysis

Compare

4 Followers

4519 Stock Chart & Stats

¥10100.00

-¥136.00(-1.98%)

At close: Jan 08 4:00 PM EST

¥10100.00

-¥136.00(-1.98%)

Day’s Range― - ―

52-Week Range¥5,942.00 - ¥10,700.00

Previous CloseN/A

Volume1.90M

Average Volume (3M)2.77M

Market Cap

¥15.50T

Enterprise Value¥15.02T

Total Cash (Recent Filing)¥979.70B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)31.3

Beta0.82

Next Earnings

Apr 24, 2026

EPS Estimate

63.06

Next Dividend Ex-DateN/A

Dividend Yield1.17%

Share Statistics

EPS (TTM)78.03

Shares Outstanding1,679,057,600

10 Day Avg. Volume3,088,480

30 Day Avg. Volume2,774,486

Financial Highlights & Ratios

PEG Ratio2.60

Price to Book (P/B)6.70

Price to Sales (P/S)10.78

P/FCF Ratio43.31

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥11,172.22

Price Target Upside10.62% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)297.44

Revenue Forecast (FY)¥1.34T

Bulls Say, Bears Say

Bulls Say

High ProfitabilityChugai’s very high gross and net margins reflect durable pricing power and a focus on specialty oncology and innovative medicines. Elevated margins provide recurring capacity to fund R&D, support product life‑cycle management, and absorb reimbursement pressure over the medium term.

Fortress Balance SheetNear‑zero leverage and rising equity-assets give Chugai long-term financial flexibility. A conservative balance sheet enables sustained R&D investment, opportunistic M&A or licensing, and resilience to reimbursement or market setbacks without forcing disruptive financing.

Solid Cash GenerationConsistent positive operating and free cash flow support durable capital allocation: funding R&D, dividends, and strategic collaborations. High FCF-to-income ratios signal earnings quality and reduce reliance on external funding for medium-term growth investments.

Bears Say

Uneven Revenue GrowthChugai’s revenue trajectory is uneven year‑to‑year, reflecting product life‑cycle swings and timing of launches or partner receipts. This variability complicates forecasting, increases sensitivity to single‑product performance, and can pressure investment pacing or guidance reliability.

Volatile Cash ConversionRecent weakening in cash conversion and a drop in free cash flow indicate working‑capital or timing volatility. If persistent, this can constrain near‑term R&D funding or dividend policy despite strong reported profits, reducing predictability of cash available for strategic initiatives.

Reliance On Roche PartnershipLarge reliance on Roche collaborations and partner-derived revenues creates structural exposure to partner decisions, royalty timing, and licensing terms. While strategic, this dependency can limit independent growth levers and introduce variability tied to another firm’s pipeline and commercial strategy.

Chugai Pharmaceutical Co News

Chugai and Roche Advance NXT007 Into Phase III, Raising the Stakes in Hemophilia A

Chugai Pharmaceutical Co ($CHGCF) announced an update on their ongoing clinical study. The phase III study “A Multicenter,...

19h ago

CHGCF

Chugai and Roche Advance NXT007 Into Phase III to Challenge Emicizumab in Hemophilia A

Chugai Pharmaceutical Co ($CHGCF) announced an update on their ongoing clinical study. The Phase III study “A Multicenter,...

3d ago

CHGCF

Chugai’s SAIL66 Phase I Completion: What the Latest Trial Update Means for Investors

Chugai Pharmaceutical Co ($CHGCF) announced an update on their ongoing clinical study. The Phase I study titled “A...

3d ago

CHGCF

Chugai to Replace Restricted Stock with Trust-Based Equity Incentive Plan

Chugai Pharmaceutical Co ( ($JP:4519) ) has issued an update. Chugai Pharmaceutical has decided to abolish its existing...

1M ago

Chugai Pharmaceutical Plans Sharp Dividend Hike with 100th Anniversary Payout, Signals Normalization in 2026

An announcement from Chugai Pharmaceutical Co ( ($JP:4519) ) is now available. Chugai Pharmaceutical will propose a year-end...

1M ago

Chugai’s 2025 Performance Reflected in Parent Roche’s Fiscal Results

Chugai Pharmaceutical Co ( ($JP:4519) ) has provided an announcement. F. Hoffmann-La Roche Ltd., the Swiss-headquartered parent company...

1M ago

CHGCF Earnings this Week: How Will it Perform?

Chugai Pharmaceutical Co (CHGCF) is scheduled to report 4th quarter earnings on 01/29/2026. Regarding Q4 estimates, Wall Street...

2M ago

Chugai’s DONQ52 Celiac Study Advances, Adding a New Mid‑Stage Catalyst for CHGCF

Chugai Pharmaceutical Co ($CHGCF) announced an update on their ongoing clinical study. Study Overview Chugai Pharmaceutical is running...

2M ago

CHGCF

Chugai Pharmaceutical Completes Absorption-Type Merger of Renalys Pharma

The latest announcement is out from Chugai Pharmaceutical Co ( ($JP:4519) ). Chugai Pharmaceutical has completed the process...

2M ago

Chugai Highlights Positive Phase 3 Results and FDA Filing for Lilly’s Oral GLP-1 Orforglipron

An update from Chugai Pharmaceutical Co ( ($JP:4519) ) is now available. Chugai Pharmaceutical announced that Eli Lilly...

3M ago

4519 FAQ

What was Chugai Pharmaceutical Co Ltd’s price range in the past 12 months?

Chugai Pharmaceutical Co Ltd lowest stock price was ¥5942.00 and its highest was ¥10700.00 in the past 12 months.

What is Chugai Pharmaceutical Co Ltd’s market cap?

Chugai Pharmaceutical Co Ltd’s market cap is ¥15.50T.

When is Chugai Pharmaceutical Co Ltd’s upcoming earnings report date?

Chugai Pharmaceutical Co Ltd’s upcoming earnings report date is Apr 24, 2026 which is in 42 days.

How were Chugai Pharmaceutical Co Ltd’s earnings last quarter?

Chugai Pharmaceutical Co Ltd released its earnings results on Jan 29, 2026. The company reported ¥78.03 earnings per share for the quarter, beating the consensus estimate of ¥73.975 by ¥4.055.

Is Chugai Pharmaceutical Co Ltd overvalued?

According to Wall Street analysts Chugai Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Chugai Pharmaceutical Co Ltd pay dividends?

Chugai Pharmaceutical Co Ltd pays a Notavailable dividend of ¥125 which represents an annual dividend yield of 1.17%. See more information on Chugai Pharmaceutical Co Ltd dividends here

What is Chugai Pharmaceutical Co Ltd’s EPS estimate?

Chugai Pharmaceutical Co Ltd’s EPS estimate is 63.06.

How many shares outstanding does Chugai Pharmaceutical Co Ltd have?

Chugai Pharmaceutical Co Ltd has 1,679,057,600 shares outstanding.

What happened to Chugai Pharmaceutical Co Ltd’s price movement after its last earnings report?

Chugai Pharmaceutical Co Ltd reported an EPS of ¥78.03 in its last earnings report, beating expectations of ¥73.975. Following the earnings report the stock price went down -1.634%.

Which hedge fund is a major shareholder of Chugai Pharmaceutical Co Ltd?

Currently, no hedge funds are holding shares in JP:4519

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Chugai Pharmaceutical Co Ltd

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Chugai Pharmaceutical Co (4519) Earnings & Revenues

Historic Earnings Reports

4519 Company Deck

4519 Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a balanced view with significant revenue growth and successful R&D milestones on one hand, and challenges such as project discontinuation and potential future tariff impacts on the other.View all JP:4519 earnings summaries

4519 Stock 12 Month Forecast

Average Price Target

¥11,172.22

▲(10.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6422":"¥6,422","13301":"¥13,301","8141.75":"¥8,141.8","9861.5":"¥9,861.5","11581.25":"¥11,581.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11172.222222222223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6422,8141.75,9861.5,11581.25,13301],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10145,10387.692307692309,10630.384615384615,10873.076923076924,11115.76923076923,11358.461538461539,11601.153846153846,11843.846153846154,12086.538461538461,12329.23076923077,12571.923076923076,12814.615384615385,13057.307692307691,{"y":13300,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10145,10224.017094017094,10303.034188034188,10382.051282051281,10461.068376068377,10540.08547008547,10619.102564102564,10698.119658119658,10777.136752136752,10856.153846153846,10935.170940170941,11014.188034188035,11093.205128205129,{"y":11172.222222222223,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10145,10126.153846153846,10107.307692307691,10088.461538461539,10069.615384615385,10050.76923076923,10031.923076923076,10013.076923076924,9994.23076923077,9975.384615384615,9956.538461538461,9937.692307692309,9918.846153846154,{"y":9900,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7254.135,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6576.876,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8176.526,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7490.546,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7129.434,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7230.904,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6423.092,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6597.461,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6944.229,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7952.024,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8243,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8802,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10145,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >